Literature DB >> 29368124

Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease.

Gyorgy Baffy1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) advanced to cirrhosis is often complicated by clinically significant portal hypertension, which is primarily caused by increased intrahepatic vascular resistance. Liver fibrosis has been identified as a critical determinant of this process. However, there is evidence that portal venous pressure may begin to rise in the earliest stages of NAFLD when fibrosis is far less advanced or absent. The biological and clinical significance of these early changes in sinusoidal homeostasis remains unclear. Experimental and human observations indicate that sinusoidal space restriction due to hepatocellular lipid accumulation and ballooning may impair sinusoidal flow and generate shear stress, increasingly disrupting sinusoidal microcirculation. Sinusoidal endothelial cells, hepatic stellate cells, and Kupffer cells are key partners of hepatocytes affected by NAFLD in promoting endothelial dysfunction through enhanced contractility, capillarization, adhesion and entrapment of blood cells, extracellular matrix deposition, and neovascularization. These biomechanical and rheological changes are aggravated by a dysfunctional gut-liver axis and splanchnic vasoregulation, culminating in fibrosis and clinically significant portal hypertension. We may speculate that increased portal venous pressure is an essential element of the pathogenesis across the entire spectrum of NAFLD. Improved methods of noninvasive portal venous pressure monitoring will hopefully give new insights into the pathobiology of NAFLD and help efforts to identify patients at increased risk for adverse outcomes. In addition, novel drug candidates targeting reversible components of aberrant sinusoidal circulation may prevent progression in NAFLD.

Entities:  

Keywords:  Endothelial dysfunction; Hepatic venous pressure gradient; Intrahepatic vascular resistance; Sinusoidal homeostasis

Mesh:

Year:  2018        PMID: 29368124     DOI: 10.1007/s10620-017-4903-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  138 in total

1.  The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells.

Authors:  Marina Vilaseca; Héctor García-Calderó; Erica Lafoz; Oihane García-Irigoyen; Matías A Avila; Joan Carles Reverter; Jaume Bosch; Virginia Hernández-Gea; Jordi Gracia-Sancho; Joan Carles García-Pagán
Journal:  Hepatology       Date:  2017-05-02       Impact factor: 17.425

Review 2.  The global NAFLD epidemic.

Authors:  Rohit Loomba; Arun J Sanyal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-09-17       Impact factor: 46.802

3.  Optimizing EUS-guided liver biopsy sampling: comprehensive assessment of needle types and tissue acquisition techniques.

Authors:  Allison R Schulman; Christopher C Thompson; Robert Odze; Walter W Chan; Marvin Ryou
Journal:  Gastrointest Endosc       Date:  2016-08-13       Impact factor: 9.427

Review 4.  Invasive and non-invasive assessment of portal hypertension.

Authors:  Jonathan Chung-Fai Leung; Thomson Chi-Wang Loong; James Pang; Jeremy Lok Wei; Vincent Wai-Sun Wong
Journal:  Hepatol Int       Date:  2017-03-30       Impact factor: 6.047

Review 5.  Reactive oxygen species in the control of hypoxia-inducible factor-mediated gene expression.

Authors:  Thomas Kietzmann; Agnes Görlach
Journal:  Semin Cell Dev Biol       Date:  2005 Aug-Oct       Impact factor: 7.727

6.  Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.

Authors:  Juan P Arab; Rosa M Martin-Mateos; Vijay H Shah
Journal:  Hepatol Int       Date:  2017-05-26       Impact factor: 6.047

7.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

8.  Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients.

Authors:  Jonathan Chung-Fai Leung; Thomson Chi-Wang Loong; Jeremy Lok Wei; Grace Lai-Hung Wong; Anthony Wing-Hung Chan; Paul Cheung-Lung Choi; Sally She-Ting Shu; Angel Mei-Ling Chim; Henry Lik-Yuen Chan; Vincent Wai-Sun Wong
Journal:  Hepatology       Date:  2016-07-25       Impact factor: 17.425

9.  Nonalcoholic fatty liver disease: portal hypertension due to outflow block in patients without cirrhosis.

Authors:  Masashi Hirooka; Yohei Koizumi; Teruki Miyake; Hironori Ochi; Yoshio Tokumoto; Fujimasa Tada; Bunzo Matsuura; Masanori Abe; Yoichi Hiasa
Journal:  Radiology       Date:  2014-10-10       Impact factor: 11.105

10.  Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis.

Authors:  Juan G Abraldes; Candid Villanueva; Carles Aracil; Juan Turnes; Manuel Hernandez-Guerra; Joan Genesca; Manuel Rodriguez; Jose Castellote; Juan Carlos García-Pagán; Ferran Torres; Jose Luis Calleja; Agustin Albillos; Jaime Bosch
Journal:  Gastroenterology       Date:  2016-01-14       Impact factor: 22.682

View more
  12 in total

1.  Molecular and ultrastructure study of endoplasmic reticulum stress in hepatic steatosis: role of hepatocyte nuclear factor 4α and inflammatory mediators.

Authors:  Salwa M Abo El-Khair; Fatma M Ghoneim; Dalia A Shabaan; Ayman Z Elsamanoudy
Journal:  Histochem Cell Biol       Date:  2019-10-21       Impact factor: 4.304

2.  Matrix stiffness and shear stresses modulate hepatocyte functions in a fibrotic liver sinusoidal model.

Authors:  Wang Li; Peiwen Li; Ning Li; Yu Du; Shouqin Lü; David Elad; Mian Long
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-12-09       Impact factor: 4.052

Review 3.  Idiopathic Non-Cirrhotic Portal Hypertension and Porto-Sinusoidal Vascular Disease: Review of Current Data.

Authors:  Michel Kmeid; Xiuli Liu; Samuel Ballentine; Hwajeong Lee
Journal:  Gastroenterology Res       Date:  2021-04-21

Review 4.  Targeting Liver Sinusoidal Endothelial Cells: An Attractive Therapeutic Strategy to Control Inflammation in Nonalcoholic Fatty Liver Disease.

Authors:  Xue-Kai Wang; Zong-Gen Peng
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

5.  Severe Protein-Calorie Malnutrition-Associated Hepatic Steatosis in a Woman Who Had Roux-en-Y Gastric Bypass for Morbid Obesity Thirteen Years Ago.

Authors:  Guriel N Kim; Sam Ho; David Saulino; Xiuli Liu
Journal:  Gastroenterology Res       Date:  2021-04-21

Review 6.  Generic chemoprevention of hepatocellular carcinoma.

Authors:  Sai Krishna Athuluri-Divakar; Yujin Hoshida
Journal:  Ann N Y Acad Sci       Date:  2018-09-17       Impact factor: 6.499

7.  Short-Term Western Diet Aggravates Non-Alcoholic Fatty Liver Disease (NAFLD) With Portal Hypertension in TGR(mREN2)27 Rats.

Authors:  Carla Cremonese; Robert Schierwagen; Frank Erhard Uschner; Sandra Torres; Olaf Tyc; Cristina Ortiz; Martin Schulz; Alexander Queck; Glen Kristiansen; Michael Bader; Tilman Sauerbruch; Ralf Weiskirchen; Thomas Walther; Jonel Trebicka; Sabine Klein
Journal:  Int J Mol Sci       Date:  2020-05-07       Impact factor: 5.923

Review 8.  Non-parenchymal hepatic cell lipotoxicity and the coordinated progression of non-alcoholic fatty liver disease and atherosclerosis.

Authors:  Kia M Peters; Rachel B Wilson; Nica M Borradaile
Journal:  Curr Opin Lipidol       Date:  2018-10       Impact factor: 4.776

Review 9.  Emerging Roles of Liver Sinusoidal Endothelial Cells in Nonalcoholic Steatohepatitis.

Authors:  Kunimaro Furuta; Qianqian Guo; Petra Hirsova; Samar H Ibrahim
Journal:  Biology (Basel)       Date:  2020-11-12

Review 10.  Role of Angiogenesis in the Pathogenesis of NAFLD.

Authors:  Lin Lei; Haquima Ei Mourabit; Chantal Housset; Axelle Cadoret; Sara Lemoinne
Journal:  J Clin Med       Date:  2021-03-24       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.